Insmed (INSM) Stock Soars 118% on Upbeat Lung Disease Drug Data [Yahoo! Finance]
Insmed Incorporated (INSM)
Last insmed incorporated earnings: 4/30 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.insmed.com
Company Research
Source: Yahoo! Finance
The ASPEN study evaluated two different doses of brensocatib — 10mg and 25mg — against placebo in patients with non-cystic fibrosis bronchiectasis. The study met its primary endpoint — both doses of the drug achieved statistically significant and clinically meaningful reductions in the annualized rate of pulmonary exacerbations (or episodes of worsening disease symptoms) when compared with placebo. Data from the study showed that patients in the 10 mg group experienced a 21.1% reduction in exacerbations, while those taking the 25 mg dose saw a decline of 19.4%. Treatment with the drug also achieved key secondary endpoints, including prolonged time to first pulmonary exacerbation and an increase in the odds of remaining exacerbation-free over 52 weeks. These results are based on the primary efficacy analysis of more than 1700 participants, which includes 1680 adults and 41 adolescents. Bronchiectasis is a chronic lung disease in which the bronchi (airways) can become permanently
Show less
Read more
Impact Snapshot
Event Time:
INSM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INSM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INSM alerts
High impacting Insmed Incorporated news events
Weekly update
A roundup of the hottest topics
INSM
News
- Insmed Incorporated (NASDAQ: INSM) had its price target raised by analysts at Evercore ISI from $42.00 to $75.00. They now have an "outperform" rating on the stock.MarketBeat
- Insmed Incorporated (NASDAQ: INSM) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
- Insmed Incorporated (NASDAQ: INSM) had its price target raised by analysts at JPMorgan Chase & Co. from $55.00 to $72.00. They now have an "overweight" rating on the stock.MarketBeat
- Non-cystic Fibrosis Bronchiectasis Drug Pipeline Market 2024 Featuring Zambon, AstraZeneca, Insmed, NovaBiotics, Haisco Pharmaceutical, Armata Pharmaceuticals, Chiesi Farmaceutici, & CSL Behring [Yahoo! Finance]Yahoo! Finance
- Insmed Incorporated (NASDAQ: INSM) had its price target raised by analysts at Mizuho from $36.00 to $82.00. They now have a "buy" rating on the stock.MarketBeat
INSM
Earnings
- 5/9/24 - Beat
INSM
Sec Filings
- 6/13/24 - Form 8-K
- 6/12/24 - Form 4
- 6/5/24 - Form 4
- INSM's page on the SEC website